| abstract |
The invention provides the use of a dihydrofolate reductase enzyme inhibitor selected from the group consisting of methotrexate, trimetrexate and pemetrexed; or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or for the prevention of relapses of a disease selected from the group consisting of cancer, psoriasis, psoriatic arthritis, juvenile polyarticular arthritis, rheumatoid arthritis, Crohn's disease , polymyositis, dermatomyositis and sarcoidosis, where said treatment or prevention comprises administering to a subject simultaneously, separately or sequentially a lipophilic statin and the dihydrofolate reductase enzyme inhibitor. The invention also provides a pharmaceutical composition comprising the enzyme dihydrofolate reductase inhibitor and lipophilic statin together with pharmaceutically acceptable excipients and / or carriers. |